Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPI-547 and irinotecan in recurrent or metastatic gastric cancer
NCT07364422Phase 2Not yet recruiting
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Feb 2026
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nesuparib in gastric cancer (GC), sponsored by Onconic Therapeutics Inc.. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
nesuparib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07364422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364422.